MySize reports 62% revenue growth in first quarter 2026 By Investing.com

MySize reported Q1 2026 revenue of $2.39 million, up 62% year over year, and gross profit rose 124% to $940,000, but the company still posted a net loss of $1.48 million versus $1.06 million a year ago. Operating expenses increased across the board, and the stock is down 54% over the past year, trading near its 52-week low of $0.50. Separately, Nasdaq issued a bid price deficiency notice after the shares closed below $1.00 for 30 consecutive trading days, giving the company until August 31, 2026 to regain compliance.

Analysis

The important signal here is not just operating leverage at the company level, but the tightening financing and listing overhang around micro-cap consumer-tech names. When a sub-$1 stock with weak cash coverage posts improving gross margin yet still burns capital, the market tends to re-rate the equity as a financing option rather than a business, which compresses upside even on decent top-line growth. That dynamic usually worsens into a Nasdaq notice window because any equity raise, convert issuance, or reverse split can become self-reinforcing pressure on the share price.

Second-order, this kind of consolidation-led growth can look stronger than underlying demand. If the revenue mix is being helped by acquired assets or cross-subsidiary integration, the key question becomes whether gross profit dollars are scaling faster than SG&A; here, overhead is still absorbing most of the incremental margin. That makes the path to breakeven highly sensitive to one or two quarters of execution, meaning the risk is not “business fails” but “capital structure forces dilution before operating leverage arrives.”

For listed comps and ecosystem participants, the more relevant read-through is to the market’s appetite for small-cap consumer and fashion-tech stories, not to the large-cap names in the article’s headline cluster. Weak tape in names like this often spills over into other low-float, cash-burning software or retail-adjacent microcaps because investors become more skeptical of quality-of-earnings and more demanding on balance-sheet durability. The contrarian angle is that a successful bid-price rescue can create a sharp technical squeeze, but only if paired with credible non-dilutive financing or a clean path to cash-flow inflection within the next 2-3 quarters.

Key Decisions for Investors

• Avoid long exposure to MYSZ into the Nasdaq compliance window; the most likely 30-60 day setup is dilution/RS risk rather than fundamental rerating.
• If forced to express a view, use a defined-risk short via put spreads on MYSZ for the next 2-3 months; upside is limited by micro-cap squeeze risk, but downside can accelerate on financing headlines.
• Watch for a reverse-split announcement as a tactical short-covering trigger, but fade strength unless accompanied by a capital raise on unusually favorable terms or a material reduction in cash burn.
• Pair trade: short MYSZ vs long healthier small-cap consumer/retail tech balance-sheet names; this isolates the listing-risk premium and reduces beta to broader market moves.
• For event-driven traders, consider a small speculative long only after a confirmed 10-day bid-price recovery with improving volume; otherwise risk/reward remains skewed toward capital dilution.